The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

The US Supreme Court will hear generic drug maker Hikma Pharmaceuticals USA Inc.'s challenge of an appeals court holding that ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from ...

Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

The FDA is weighing a change that could make warning labels on dietary supplements appear less often on packaging.

The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic drug makers and so-called "skinny ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

The FDA proposes front-of-package "Nutrition Info boxes" to highlight saturated fat, sodium, and added sugars. The initiative aims to combat chronic diseases and promote healthier food choices. Large ...

The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential ​risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli ...